The decentralized science (DeSci) platform Bio Protocol has received support from investors such as Maelstrom Fund and Animoca Brands, aiming to expand the AI-native biotechnology research framework.
Bio Protocol announced on Wednesday that it has successfully raised $6.9 million, as interest in decentralized drug development methods that integrate AI, blockchain, and community participation continues to grow.
Arthur Hayes, founder of Maelstrom, believes that Bio Protocol has the potential to become "an incubator platform that defines the industry category." He stated, "If it works well, this is not just an incubator platform—it's the birth of an AI-native scientific research market."
Hayes also pointed out that the platform provides the community with research opportunities that interest them, rather than just topics of concern to academia.
Cointelegraph has reached out to Maelstrom and Animoca for more information but has not received a response as of the time of publication.
DeSci is a movement that aims to change the way scientific research is conducted, funded, and shared through blockchain technology, crypto incentives, and decentralized governance.
Bio Protocol stated that the platform accelerates scientific progress by integrating cryptocurrency and AI. Its blockchain-based approach enables fundraising and collaboration, thereby shortening drug development cycles.
Researchers do not have to wait for years for traditional funding or establish partnerships with pharmaceutical companies; they can propose hypotheses, connect on-chain wallets, and directly use community-raised funds for experiments with the help of decentralized AI agents called "BioAgents."
Every step of the process will be recorded on-chain, ensuring that contributors receive recognition and preserving an immutable record of research progress.
The protocol also employs cryptocurrency-based incentive mechanisms to promote research progress, including intellectual property tokenization, token staking mechanisms, and loyalty reward systems, allowing investors, researchers, and community members to align around common goals.
Simon Dedic, founder of Moonrock Capital and one of the investors in Bio Protocol, noted that the early development of DeSci "sometimes looks like a meme," but Bio Protocol is expected to play a key role in improving the academic science system.
Simon Dedic stated, "I come from the academic science field myself and am very aware of the serious incentive misalignment in the system, which leads to fatal consequences in various aspects." He added that the project is expected to revitalize science.
The company positions itself within the DeSci movement, aiming to reduce reliance on universities, government funding, and pharmaceutical companies while making research more accessible to the community and independent scientists.
Related: The first ETF for Dogecoin is launched; how high can DOGE prices go?
Original article: “Maelstrom and Animoca Capital join forces to strategically invest in Bio Protocol to build a triangle ecosystem of AI + biotechnology + cryptocurrency”
免责声明：本文章仅代表作者个人观点，不代表本平台的立场和观点。本文章仅供信息分享，不构成对任何人的任何投资建议。用户与作者之间的任何争议，与本平台无关。如网页中刊载的文章或图片涉及侵权，请提供相关的权利证明和身份证明发送邮件到support@aicoin.com，本平台相关工作人员将会进行核查。
